盈康生命(300143) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 reached ¥361,417,574.60, representing a 35.09% increase compared to ¥267,547,194.29 in the same period last year[4] - Net profit attributable to shareholders for Q1 2023 was ¥39,550,000.16, a 64.07% increase from ¥24,105,210.83 year-on-year[4] - The basic earnings per share for Q1 2023 was ¥0.0616, up 64.27% from ¥0.0375 in Q1 2022[5] - Total operating revenue for Q1 2023 was CNY 361,417,574.60, an increase of 35.0% compared to CNY 267,547,194.29 in Q1 2022[30] - Net profit for Q1 2023 reached CNY 39,591,017.54, up 48.0% from CNY 26,705,857.97 in the same period last year[31] - Operating profit for the quarter was CNY 47,469,023.13, representing a 35.2% increase from CNY 35,100,174.65 in Q1 2022[30] - The weighted average return on equity for Q1 2023 was 3.04%, up from 1.35% in the same period last year[5] Cash Flow and Assets - The company reported a cash flow from operating activities of ¥38,669,216.63, an increase of 7.82% compared to ¥35,865,963.18 in the previous year[4] - Cash generated from operating activities was CNY 356,067,966.47, an increase from CNY 295,614,194.14 in the same quarter last year[33] - The net cash flow from operating activities for Q1 2023 was ¥38,669,216.63, an increase from ¥35,865,963.18 in Q1 2022, reflecting a growth of approximately 4.5%[34] - Total assets at the end of Q1 2023 were ¥2,106,624,880.96, reflecting a 3.09% increase from ¥2,027,856,490.51 at the end of the previous year[5] - As of March 31, 2023, total assets amounted to RMB 2,106.62 million, an increase from RMB 2,043.51 million at the beginning of the year[28] - Cash and cash equivalents decreased to RMB 412.69 million from RMB 433.18 million at the beginning of the year, reflecting a decline of approximately 4.3%[27] Investments and Research - The company launched 21 new technologies and projects in the medical field during the reporting period, focusing on enhancing diagnostic and treatment capabilities[9] - Research and development expenses increased to CNY 12,728,463.50, a rise of 158.5% compared to CNY 4,916,338.15 in the previous year[30] - The company is focusing on expanding its investment in biotechnology, medical devices, and high-end equipment through partnerships with investment institutions[23] - The total investment for the medical device smart ecosystem project is estimated at RMB 566.11 million, funded by self-owned and self-raised funds[22] Market and Product Development - Internet medical revenue grew by 205% year-on-year, reaching ¥15,520,000 in Q1 2023[11] - The company's infusion products market share increased to 8.14%, ranking fourth in 2022, with sales growth of 304% year-on-year due to the post-pandemic ICU expansion[14] - The company received four new scientific research certificates for its breast imaging products, enhancing its reputation and development capabilities in high-end breast imaging diagnostic equipment[15] - The company launched a complete solution for future hospital scenarios, optimizing seven key areas including nursing treatment and environmental control, establishing an industry brand[13] - The company’s new temperature management product, a medical warming blanket, received registration approval, aimed at reducing heat loss during surgery and shortening recovery time[14] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 17,810, with the largest shareholder, Qingdao YK Medical Investment Co., Ltd., holding 39.69% of shares[17] - The company plans to fully unlock executive restricted shares by March 13, 2024, with a total of 7,875 shares for one executive and 5,625 shares for another[21] - The company’s stockholder Ji Zihao holds a total of 8,312,457 shares, including shares held through a margin trading account[19] Liabilities and Financial Position - Total liabilities as of the end of Q1 2023 were CNY 755,215,518.01, up from CNY 726,165,177.60 at the end of Q1 2022[30] - The company's total equity increased to CNY 1,351,409,362.95, compared to CNY 1,317,343,672.12 in the previous year[30] - Current liabilities include short-term borrowings of RMB 15.82 million, down from RMB 16.72 million, a decrease of about 5.4%[28] - Accounts payable increased to RMB 160.78 million from RMB 147.75 million, representing an increase of approximately 8.8%[28] Cash Flow Activities - Total cash inflow from operating activities amounted to ¥363,282,348.43, compared to ¥301,270,724.17 in the previous year, indicating a year-over-year increase of about 20.6%[34] - Cash outflow from operating activities was ¥324,613,131.80, up from ¥265,404,760.99 in Q1 2022, representing an increase of approximately 22.3%[34] - The net cash flow from investing activities was -¥57,320,837.17, worsening from -¥11,994,538.38 in the same quarter last year[34] - Cash outflow for investing activities reached ¥59,320,870.17, significantly higher than ¥12,056,846.38 in Q1 2022[34] - The net cash flow from financing activities was -¥1,690,284.22, compared to -¥3,724,861.11 in Q1 2022, showing an improvement of approximately 54.7%[35] - The total cash and cash equivalents at the end of Q1 2023 were ¥412,685,925.67, down from ¥681,641,103.56 at the end of Q1 2022, a decrease of about 39.5%[35] Miscellaneous - The company did not conduct an audit for the Q1 2023 report[36] - The company expanded its clinical promotion of the shortwave therapy device to several hospitals, including Xiangya Hospital and Shanghai First Maternity and Infant Hospital[15] - The company is focusing on digital therapies and home health monitoring systems to enhance patient care and recovery management[13]